TAS1R2

Across TCGA pan-cancer cohorts, TAS1R2 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated TAS1R2 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TAS1R2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAS1R2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

MESO, BLCA, and READ are the cancer types where TAS1R2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.069	0.580	<.001	27	view →
BLCA	OS	Median	II,III,IV	1.000	0.407	.013	18	view →
READ	OS	Median	III,IV	0.644	0.932	<.001	16	view →
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →
BRCA	OS	Median	All	0.110	0.578	.027	12	view →
HNSC	OS	Median	III,IV	0.002	0.746	<.001	12	view →
KIRP	OS	Median	II,III,IV	0.176	0.743	.007	9	view →
SARC	DFS	Median	All	0.079	0.613	<.001	6	view →
LUAD	OS	Median	All	0.580	0.837	.018	6	view →
UCEC	DFS	Median	All	0.893	0.589	.023	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

TAS1R2–MESO (OS)

Open the MESO breakdown →